Silence Therapeutics Plc - American Depository Share — 분기별 재무 통계 (NASDAQ:SLN)

Financials

영업활동으로 인한 현금 -27.48 M-12.31 M-21.78 M-10.89 M-17.29 M-15.6 M -65.56 M 투자 활동으로 인한 현금 66.13 M-44.38 M-1.56 M51.29 M-53.34 M10 M 6.39 M 재무활동으로 인한 현금 -98 K14 K1 000000 1 000 잉여 현금 흐름 -27.48 M-12.31 M-21.78 M-10.89 M-17.29 M-15.6 M -65.56 M

Silence Therapeutics Plc - American Depository Share

Silence Therapeutics is a London-based pharmaceutical company formed in 1994. The company has pioneered the development of short-interfering ribonucleic acid therapeutics for the treatment of rare diseases. Silence Therapeutics has offices in London, New Jersey, and Berlin, with its corporate headquarters located in Hammersmith, London.

SLN

Financials

Silence Therapeutics Plc - American Depository Share

뉴스

Silence Therapeutics (SLN) Soars 19.0%: Is Further Upside Left in the Stock?

Silence Therapeutics Q4 실적 예상치를 넘어, 수익 에상치보다 저조

Silence Therapeutics earnings beat by $0.11, revenue fell short of estimates

제퍼리스, 사일런스 테라퓨틱스에 ’매수’ 의견 재확인… 데이터 발표 기대

Jefferies reiterates Buy on Silence Therapeutics stock ahead of data

Wall Street Analysts See a 467.47% Upside in Silence Therapeutics (SLN): Can the Stock Really Move This High?

사일런스 테라퓨틱스, 다이버시란 잠재력에 힘입어 긍정적 전망 유지

William Blair reiterates Silence Therapeutics stock rating on divesiran potential

H.C. 웨인라이트, 사일런스 테라퓨틱스에 ’매수’ 등급 재확인

H.C. Wainwright reiterates Buy rating on Silence Therapeutics stock at $75

사일런스 테라퓨틱스, Rhonda Hellums CFO 이사회 임명

트리프로그, 신임 CEO로 마크 로세라 임명